Categories
Change Password!
Reset Password!
Tapinarof cream 1% shows favorable tolerability, with minimal interruption due to follicular events or contact dermatitis in psoriasis and atopic dermatitis.
A growing body of clinical and real-world evidence highlights tapinarof (aryl hydrocarbon receptor agonist) cream 1% as a well-tolerated and flexible topical therapy for adults with plaque psoriasis and atopic dermatitis (AD), with minimal treatment disruption due to side effects.
Researchers reviewed key data from major clinical trials—PSOARING (psoriasis) and ADORING (AD)—to better comprehend the incidence, clinical presentation, and management of follicular reactions and contact dermatitis associated with tapinarof use. These findings were further supported by dermatologists’ real-world clinical experience, including combination therapy settings.
Key findings from trials and clinical practice
Tapinarof cream 1% stands out as a novel, non-steroidal topical option with:
To sum up, tapinarof cream 1% offers an effective and patient-friendly treatment choice for plaque psoriasis and AD. Follicular reactions and contact dermatitis are uncommon, usually mild, and rarely interfere with ongoing therapy, reinforcing tapinarof’s role as a reliable addition to modern dermatologic care.
Journal of Dermatological Treatment
Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis
Linda Stein Gold et al.
Comments (0)